Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Millennium Pharmacon International Tbk (ISX:SDPC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
PT Millennium Pharmacon International Tbk's Enterprise Value for the quarter that ended in Mar. 2026 was Rp1,055,549 Mil.
PT Millennium Pharmacon International Tbk's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp110,793 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk EV-to-EBIT Related Terms
PT Millennium Pharmacon International Tbk EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk EV-to-EBIT Chart
PT Millennium Pharmacon International Tbk Annual Data
For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Millennium Pharmacon International Tbk EV-to-EBIT vs Medical Distribution Industry
PT Millennium Pharmacon International Tbk's current Enterprise Value is Rp1,040,261 Mil.
PT Millennium Pharmacon International Tbk's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp110,793 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Millennium Pharmacon International Tbk (ISX:SDPC) has a EV-to-EBIT of 9.39 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Millennium Pharmacon International Tbk and its competitors. This is near median its historical median of 9.15. Over the past decade, PT Millennium Pharmacon International Tbk's EV-to-EBIT has ranged from 6.68 to 16.37. According to the industry distribution chart, PT Millennium Pharmacon International Tbk ranks #38 out of 94 companies in the Medical Distribution industry, placing it in the top 40.4%.
Is PT Millennium Pharmacon International Tbk's EV-to-EBIT too high?
PT Millennium Pharmacon International Tbk's current EV-to-EBIT of 9.39 is near median its 10-year median of 9.15. Over the past 10 years, this metric has ranged from a low of 6.68 to a high of 16.37. The Medical Distribution industry median EV-to-EBIT is 11.55. PT Millennium Pharmacon International Tbk's value of 9.39 is 18.7% below this industry median. Based on the distribution chart, PT Millennium Pharmacon International Tbk ranks #38 out of 94 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, PT Millennium Pharmacon International Tbk has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Millennium Pharmacon International Tbk's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Millennium Pharmacon International Tbk ranks #38 out of 94 companies for EV-to-EBIT. This puts PT Millennium Pharmacon International Tbk in the upper half of its industry. The industry median EV-to-EBIT is 11.55. PT Millennium Pharmacon International Tbk's value of 9.39 is 18.7% below this benchmark. Historically, PT Millennium Pharmacon International Tbk's own EV-to-EBIT has ranged from 6.68 to 16.37 over the past decade. While the company's 10-year median is 9.15 vs. the industry median of 11.55, PT Millennium Pharmacon International Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.55, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Millennium Pharmacon International Tbk's current EV-to-EBIT of 9.39 is 18.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on PT Millennium Pharmacon International Tbk and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Millennium Pharmacon International Tbk's current EV-to-EBIT is 9.39, which is near median its own 10-year median of 9.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Millennium Pharmacon International Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk (ISX:SDPC) is currently considered Fairly Valued. The stock's GF Value™ is Rp166.83, compared to a current price of Rp181.00 — trading 8.5% above its estimated fair value. The current EV-to-EBIT is 9.39, which is near median its 10-year median of 9.15 and 18.7% below the Medical Distribution industry median of 11.55. PT Millennium Pharmacon International Tbk's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For PT Millennium Pharmacon International Tbk (ISX:SDPC), the current EV-to-EBIT is 9.39 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Millennium Pharmacon International Tbk (ISX:SDPC) Overvalued in 2026?
Based on GuruFocus' analysis, PT Millennium Pharmacon International Tbk stock appears to be overvalued.
The current stock price of Rp181.00 is trading 8.5% above its estimated GF Value™ of Rp166.83.
GuruFocus considers PT Millennium Pharmacon International Tbk to be Fairly Valued.
Key valuation signals for ISX:SDPC:
EV-to-EBIT: 9.39 (near median its 10-year median of 9.15)
GF Value™: Rp166.83 vs. price of Rp181.00 (8.5% above fair value)
Industry Position: 18.7% below the Medical Distribution median (#38 of 94)
No single metric tells the full story. See the ISX:SDPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressJl. Sultan Iskandar Muda No 18/Jl. Bungur No. 1, Crown Bungur Arteri Lantai 2-4, Kel. Kebayoran Lama Selatan, Kec. Kebayoran Lama, South Jakarta, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The group's operating segments are Prescription medicine, Non-prescription medicine, Medical Disposables, and others, of which the majority of revenue is derived from the Prescription Medicine segment. The company's geographical segments are Jawa, Sumatra, Kalimantan, Sulawesi, and Bali & Lombok.
79GF Score
Get the complete analysis for ISX:SDPC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SDPC has been successfully added to your 
